AUTHORS
Ravi Kumar Gupta, MD, Angela Krach2, Katie B Schaneville3, Muzaffar Qazilbash, MD4, Qaiser Bashir, MD5, Neeraj Saini, MD6, Yosra M. Aljawai, MD MS7, Warren Fingrut, MD, MPH8, William Matsui, MD9, Mahmoud R. Gaballa, MD10, Oren Pasvolsky, MD11, Jing Christine Ye, M.D., MSc12, Sarvari V. Yellapragada, MD13, Krina Patel Jr, MD, MSc14, Robert Orlowski, MD, PhD15, Richard Champlin16, Elizabeth Shpall, MD17, Paul Lin, MD, PhD18
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction: In multiple myeloma (MM), the standard of care quadruplet induction regimen (D-RVD) has been found to negatively impact the ability to collect CD34+ cells for autologous stem cell transplantation (Pasvolsky et al, Blood (2025) 146 (Supplement 1): 7557). Motixafortide, a long-acting CXCR4 antagonist, was recently approved for stem cell collection. However, its use in the salvage setting is unstudied. Here we report a single-center experience with with motixafortide as a second- or third-line collection attempts (Mob#2, Mob#3) as compared to chemo-mobilization.
Methods: We conducted a retrospective analysis of adults with MM who failed to collect 2×10⁶ CD34+ cells/kg with plerixafor + G-CSF at first attempt (Mob#1) and were subsequently given motixafortide + G-CSF, and/or cyclophosphamide + G-CSF + plerixafor (chemo-mob) as Mob#2 and Mob#3 between July 2024 and June 2026; 33 distinct patients were analyzed, 4 of whom contribute to both groups. Three patients received motixafortide + cyclophosphamide + G-CSF and are reported separately. Our ideal collection goal was 4x10⁶ CD34+ cells/kg, though patients with >2×10⁶ CD34+ cells/kg can proceed to transplant. The interval between attempts (REST) is defined as the day from the last collection to the start of either G-CSF or chemotherapy. Patients receiving motixafortide were premedicated with famotidine, motelukast, acetaminophen, dexamethasone 4 to 20 mg and diphenhydramine 12.5 to 50 mg.
Results: Median age was 67.5 years (range 45 to 78). Thirty-three patients were evaluated. After Mob#1, patients collected a median of 1.31×10⁶/kg (0.07 to 2.85), with 7 of 33 (21%) collecting >2×10⁶/kg. In Mob#2, patients receiving motixafortide (n=24) had a median collection of 1.75×10⁶/kg (range 0.07 to 5.22). Eight of 24 (33%) collected 2-4×10⁶/kg and 2 (8%) collected >4×10⁶/kg. Twenty patients (83%) collected enough total cells (combining Mob#1 and Mob#2) for transplantation. In patients who received chemo-mob for Mob#2 (n=9), the median collection was 2.06×10⁶/kg. Five (56%) collected 2-4×10⁶/kg and none collected >4×10⁶/kg.Eight patients (89%) collecting enough total cells for transplantation. In Mob#3, 2 patients received motixafortide with an average collection of 2.54×10⁶/kg with both patients able to proceed with transplant. Two patients received chemo-mob for Mob#3, with an average collection of 1.17×10⁶/kg with one patient collecting enough total cells for transplantation. Three patients received chemo-mobilziation with motixafortide for Mob#2 with an average collection of 1.82×10⁶/kg (range 1.42 to 2.44).
When analyzing the interval between attempts (REST), patients who received motixafortide <7 days after the last collection attempt (n=7) collected a median of 1.05×10⁶/kg (range 0.07 to 1.93). Patients who received chemo-mob (n=7) were able to collect a median of 1.73×10⁶/kg (range 0.15 to 3.95). In patients who had a REST of 8-14 days, those who received motixafortide (n=4) collected a median of 2.48×10⁶/kg (range 1.41 to 2.87), while the single patient who received chemo-mob (n=1) collected 2.19×10⁶/kg. In patients who had a REST >14 days, those who received motixafortide (n=15) collected a median of 2.36 (range 0.6 to 5.22), those who received chemo-mob (n=3) collected a median of 2.18×10⁶/kg (range 1.99 to 2.54).
Reactions to motixafortide occurred in 11 of 26 (42%): grade 1 in 5, grade 2 in 4 and ungraded in 2, with none recorded as grade 3 or higher.
Conclusion: Given the increased difficulty of collecting sufficient stem cells for transplantation with the newer quadruplet induction regimen, there exists a need for alternative methods for collection. Here we show that while overall collection is significantly lower than upfront collection as reported in the GENESIS trial, motixafortide remains a viable option for patients as either a second or third attempt at collection. Furthermore, it canpotentially be used as third attempt when patients fail to collect after both plerixafor and with chemo-mobilization. Of note, unlike in chemo-mob, patients who receive motixafortide should rest at least 8 days after the last collection. Reactions with motixafortide were common, but manageable.
DISCLOSURES
Ravi Kumar Gupta, MD: No relevant conflicts of interest to declare.